Exabis Library
Welcome to the e-CCO Library!
P492: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P492: The UC Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A prospective open label pilot study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P493 Segmental colectomy vs. extended colectomy for colonic Crohn’s disease: results from 112 consecutive patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P493: Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P493: Cost-effectiveness of venous thromboembolism prophylaxis after hospitalization in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P493: Efficacy of anti-TNF for internal fistula in Crohn's disease – results from a retrospective multicenter cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P493: Inflammatory sticturing Crohn’s diseases: results of medical treatment
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P493: Prevalence and risk factors for postoperative septic complications in Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P493: QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P493: The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P494 The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P494: A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P494: Can Patients Monitor Response To Ustekinumab In The Real World?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P494: Impact of early optimization of ustekinumab on mid-term targets in severe Crohn's disease: THE MUST study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P494: Monocytic TNF production predicts response to infliximab treatment in Crohn’s disease but not ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P494: Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P494: Phenotypic analysis revealed features of disease severity in familial versus sporadic cases of inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P494: Regional survey on satisfaction with healthcare in inflammatory bowel disease patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P495 Usefulness of a capsule endoscopy scoring system in understanding the disease state of Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P495: Biosimilar infliximab is effective and safe in inflammatory bowel disease patients naïve to anti-TNF therapy: a tertiary centre experience
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM